Skip to main content
. 2015 Jul 23;6(29):27252–27266. doi: 10.18632/oncotarget.4583

Figure 3. Co-treatment with poly-ICLC and Sorafenib impairs tumor cell survival and proliferation.

Figure 3

Hepa 1-6 cells were either treated with vehicle (Ctl), poly-ICLC (pIC), Sorafenib (S) or a combination of both (pIC+S) at 37°C. A. Enhanced cell death was observed as an increased percentage of Annexin-V+Topro-3+ cells after 48 h treatment with pIC+S: 59.5 ± 4.6% vs. Ctl: 29.1 ± 7.3%, p = 0.004, and vs. S: 34.4 ± 7.1%, p = 0.01. Right, representative dot plots showing increased Annexin-V+Topro-3+ population among Hepa 1-6 cells treated with pIC+S. B. Representative light microscopy images of Hepa 1-6 cells in culture showing enhanced cell death after pIC+S treatment for 48 h (100× magnification). C. Inhibition of Hepa 1-6 cell proliferation as measured by thymidine incorporation (Log) at 24 h after treatment with pIC+S: 3.4 ± 0.1 vs. Ctl: 4.8 ± 0.5, p = 0.03 and vs. pIC: 4.9 ± 0.2, p = 0.005. D. Enhanced cell death and E. inhibition of cell proliferation were observed in SNU449 and SNU475 cells after treatment with pIC+S. For all graphs, mean and SD were shown. *p < 0.05; **p < 0.01, paired Student's t-test, n = 3 independent experiments.